Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 11/20 | 0.43 |
| ▸ | F7 | P08709 | 11/20 | 0.43 |
| ▸ | F10 | P00742 | 10/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.36 |
| ▸ | SCN2B | O60939 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11026899 | 0.90 | F11 (0.45) | F11F7F10SCN9ACA1 | |
| SCHEMBL11024582 | 0.86 | F7 (0.43) | F11F7F10IP6K1SCN9A | |
| SCHEMBL11940893 | 0.86 | F11 (0.38) | F11F7F10IP6K1SCN9A | |
| SCHEMBL11940891 | 0.84 | SCN9A (0.42) | F11F7F10IP6K1SCN9A | |
| SCHEMBL11026541 | 0.83 | KDM1A (0.41) | F11F7F10 | |
| SCHEMBL11028722 | 0.83 | F11 (0.53) | F11F7F10 | |
| SCHEMBL11940885 | 0.83 | SCN9A (0.48) | F11F7F10IP6K1SCN9A | |
| SCHEMBL11940901 | 0.83 | SCN9A (0.39) | F11F7F10IP6K1SCN9A | |
| SCHEMBL11024205 | 0.82 | F11 (0.52) | F11F7F10 | |
| SCHEMBL11940894 | 0.81 | F11 (0.42) | F11F7F10SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | RAB1A, RABL3, RAB7A | F11 2989/4885F7 2297/4885F10 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.